Mabpharm Ltd. (2181)

Overview

Mabpharm Limited operates within the biopharmaceutical field, focusing on the research, development, and production of innovative drugs and biosimilar drugs, primarily targeting cancers and autoimmune diseases. This operation extends across the People's Republic of China. Since its incorporation in 2018, the company has established its headquarters in Taizhou, harnessing its expertise to make significant strides in medical research and development. Mabpharm places a strong emphasis on leveraging biotechnological advances to create therapeutic solutions that address some of the most challenging medical conditions, marking a significant presence within its industry sector.

Products and Services

CMAB007: A recombinant humanized anti-immunoglobulin E monoclonal antibody in Phase III clinical trials, targeting asthma patients. This advanced treatment option represents Mabpharm's commitment to addressing respiratory conditions with cutting-edge biotechnology.

CMAB009: This product, a recombinant anti-EGFR chimeric monoclonal antibody, is aimed at the first-line treatment of metastatic colorectal cancer. Currently under Phase III clinical trials, it epitomizes the company's focus on providing new hope for cancer patients.

CMAB008: Designed for patients with moderate to severe active rheumatoid arthritis, CMAB008 is a recombinant anti-TNF-alpha chimeric monoclonal antibody. It is being tested in Phase III clinical trials, reflecting Mabpharm’s dedication to fighting autoimmune diseases.

CMAB807: A product in Phase III clinical trial stages for treating osteoporosis indications. Mabpharm is extending its research to cover a wide range of debilitating diseases, including bone health disorders.

CMAB819: Currently in Phase I clinical trials, CMAB819 is targeted at treating metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas. This exemplifies the company's broad approach to tackling various cancer types.

CMAB807X: Focused on the treatment of tumor bone metastasis, showcasing Mabpharm's ongoing efforts to combat cancer-related complications with innovative biotechnological solutions.

CMAB015: A biosimilar candidate for secukinumab, under development to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. Mabpharm is also focusing on creating biosimilar drugs, which are essential for providing more accessible treatment options to patients worldwide.

Pre-clinical stage products: Including CMAB017 for advanced solid tumors, CMAB018 (a biosimilar candidate for mepolizumab) for asthma and eosinophilic granulomatous polyangiitis, and CMAB022 for inflammatory diseases, Mabpharm is developing a robust pipeline that covers a wide array of conditions, demonstrating its commitment to advancing healthcare through innovation.

In addition to its impressive portfolio of pharmaceuticals, Mabpharm offers a range of services including research and development, technical consulting, technology transfer, and technical services related to biological products, diagnostic reagents, chemical biological reagents, and drugs. This comprehensive approach to biopharmaceutical development and support underscores the company's role as a full-spectrum provider in the biotech industry.